Skip to main content
. 2021 May 21;122(3):353–362. doi: 10.1055/a-1515-9529

Table 1. Characteristics of patients included in cohort A.

Patient characteristics All patients,
n  = 50
Patients with grade 3 ascites,
n  = 25
Patients without ascites,
n  = 25
p -Value
(patients with grade 3 ascites vs. without ascites)
Age, y 57.8 ± 11.9 57.3 ± 15 58.3 ± 8 0.775
Sex
 Male 37 (74%) 4 (16%) 9 (36%) 0.196
 Female 13 (26%) 21 (84%) 16 (64%)
Etiology
 Viral 15 (30%) 5 (20%) 10 (40%) 0.012
 ALD 22 (44%) 16 (64%) 6 (24%)
 NAFLD or cryptogenic 10 (20%) 2 (8%) 8 (32%)
 Other 3 (6%) 2 (8%) 1 (4%)
Varices 39 (78%) 20 (80%) 19 (76%) 0.733
History of variceal bleeding 12 (24%) 5 (20%) 7 (28%) 0.508
Hepatic encephalopathy 20 (40%) 17 (68%) 3 (12%) <0.001
HVPG, mmHg 20.6 ± 4.4 21.4 ± 4.8 19.9 ± 4 0.229
MELD, points 13 (11–15) 13 (12–17) 12 (10–15) 0.281
CTP score, points 8 (6–10) 9 (9–11) 6 (6–7) <0.001
 A 13 (26%) 0 (0%) 13 (52%) <0.001
 B 23 (46%) 13 (52%) 10 (40%)
 C 14 (28%) 12 (48%) 2 (8%)
Albumin, g/L 32.7 ± 5.21 30.9 ± 4.1 34.5 ± 5.6 0.013
Bilirubin, mg/dL 1.47 (0.99–2.5) 2.02 (1.09–3.45) 1.41 (0.94–2.12) 0.281
INR 1.4 (0.2) 1.4 (1.3–1.5) 1.5 (1.25–1.65) 0.281
Creatinine, mg/dL 0.76 (0.668–0.915) 0.89 (0.72–1.09) 0.72 (0.605–0.775) 0.016
CRP, mg/L 0.68 (0.275–1.29) 1.15 (0.645–2.09) 0.32 (0.105–0.745) 0.001
IL-6, µg/mL 14.8 (7.8–36.7) 29.9 (20.1–46.4) 8.02 (3.57–13.3) <0.001
LBP, µg/mL 7.84 ± 3.68 9.31 ± 3.48 6.37 ± 3.31 0.004

Abbreviations: ALD, alcoholic liver disease; CRP, C-reactive protein; CTP, Child–Turcotte–Pugh score; HVPG, hepatic venous pressure gradient; IL-6, interleukin 6; INR, international normalized ratio; LBP, lipopolysaccharide binding protein; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease.

Note: Categorical variables are reported as numbers and proportions of patients, while continuous variables are shown as mean ± standard deviation or median (interquartile range [IQR]), as appropriate.